Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Passes Above 200 Day Moving Average – Time to Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.30 and traded as high as $5.00. Ironwood Pharmaceuticals shares last traded at $4.86, with a volume of 1,594,030 shares traded.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IRWD. Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st. Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 29th. Craig Hallum raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Wells Fargo & Company lifted their price objective on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the company an “equal weight” rating in a research note on Monday, January 5th. Finally, Citigroup upgraded Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $3.68.

Ironwood Pharmaceuticals Trading Up 1.5%

The business’s fifty day moving average price is $3.92 and its 200-day moving average price is $2.30. The company has a market capitalization of $790.62 million, a P/E ratio of 30.38 and a beta of 0.18.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative return on equity of 15.17% and a net margin of 8.70%.The business had revenue of $122.06 million for the quarter, compared to analysts’ expectations of $74.22 million. As a group, equities research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter worth approximately $25,000. Integrated Wealth Concepts LLC raised its position in Ironwood Pharmaceuticals by 21.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,406 shares during the period. R Squared Ltd lifted its stake in Ironwood Pharmaceuticals by 286.5% in the second quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 28,735 shares during the last quarter. Focus Partners Advisor Solutions LLC boosted its position in Ironwood Pharmaceuticals by 284.6% during the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 29,409 shares during the period. Finally, Captrust Financial Advisors purchased a new stake in Ironwood Pharmaceuticals during the second quarter valued at about $32,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.